


文档简介
1、Product Data SheetCalicheamicinCat. No.: HY-19609CAS No.: 108212-75-5分式: CHINOS分量: 1368.35作靶点: DNA Alkylator/Crosslinker; ADC Cytotoxin; Bacterial; Apoptosis作通路: Cell Cycle/DNA Damage; Antibody-drug Conjugate/ADC Related; Anti-infection;Apoptosis储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 mo
2、nths-20C 1 month溶解性数据体外实验 DMSO : 100 mg/mL (73.08 mM)H2O : 0.1 mg/mL (insoluble)* means soluble, but saturation unknown.SolventMass1 mg 5 mg 10 mgConcentration制备储备液1 mM 0.7308 mL 3.6540 mL 7.3081 mL5 mM 0.1462 mL 0.7308 mL 1.4616 mL10 mM 0.0731 mL 0.3654 mL 0.7308 mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;旦配成溶液
3、,请分装保存,避免反复冻融造成的产品失效。储备液的保存式和期限:-80C, 6 months; -20C, 1 month。-80C 储存时,请在 6 个内使,-20C 储存时,请在 1 个内使。体内实验请根据您的实验动物和给药式选择适当的溶解案。以下溶解案都请先按照 In Vitro 式配制澄清的储备液,再依次添加助溶剂:为保证实验结果的可靠性,澄 的储备液可以根据储存条件,适当保存;体内实验的作液,建议您现现配,当天使; 以下溶剂前显的百分 指该溶剂在您配制终溶液中的体积占;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的式助溶1. 请依序添加每种溶剂: 10% DMSO 40%
4、 PEG300 5% Tween-80 45% salineSolubility: 3 mg/mL (2.19 mM); Clear solution此案可获得 3 mg/mL (2.19 mM,饱和度未知) 的澄清溶液。以 1 mL 作液为例,取 100 L 30.0 mg/mL 的澄 DMSO 储备液加到 400 L PEG300 中,混合均匀;向上述体系中加50 L Tween-80,混合均匀;然后继续加 450 L 理盐定容 1 mL。2. 请依序添加每种溶剂: 10% DMSO 90% corn oilPage 1 of 2 www.MedChemESolubility: 3 mg/
5、mL (2.19 mM); Clear solution此案可获得 3 mg/mL (2.19 mM,饱和度未知) 的澄 溶液,此案不适于实验周 期在半个以上的实验。以 1 mL 作液为例,取 100 L 30.0 mg/mL 的澄 DMSO 储备液加到 900 L 油中,混合均匀。BIOLOGICAL ACTIVITY物活性 Calicheamicin种肿瘤抗素,也是有效的细胞毒性试剂,可引起DNA双链断裂。Calicheamicin 抑制 DNA 合成。IC & Target Calicheamicins体外研究 PF-06647263 (anti-EFNA4-ADC) is genera
6、ted via conjugation of hE22 lysine residues to the AcButDMH-N-Ac-calicheamicin-1 linker-payload with an average drug-to-antibody ratio (DAR) of 4.6. PF-06647263 elicits antigen-and concentration-dependent cytotoxicity, as exposure to PF-06647263 for 96 hours results in cell death (EC50= appr1 ng/mL)
7、1. CMC-544, consisting of a humanized CD22 Ab linked to calicheamicin, is effective in pediatric primary B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells in vitro. CMC-544 induces cell death in various ALL celllines in a dose- and time-dependent way, with IC50 values ranging from 0.15 t
8、o 4.9 ng/mL. CMC-544 (10 ng/mL) iseffective and specific in primary BCP-ALL cells2. In CMC-544-treated cells, the level of CD22 has decreased relative tothat on G5/44-treated cells and continued to decrease3.体内研究 An ADC comprising a humanized anti-EFNA4 monoclonal antibody conjugated to the DNA-dama
9、ging agentcalicheamicin achieves sustained tumor regressions in both TNBC and ovarian cancer PDX in vivo. PF-06647263 (0.27,0.36 mg/kg) results in significant tumor regressions in TNBC xenografts1.PROTOCOLCell Assay 3 The enhancement of the CDC effect is studied in a similar way in the presence of C
10、MC-544 or G5/44. Specifically,after cells are incubated with or without CMC-544 (5 ng/mL calichemicin DMH) or G5/44 at 37C for 2 h, they arewashed three times to remove unbound antibodies. The viability of cells before incubation with CMC-544 is 99.8%.After the cells are re-incubated in CMC-544- and
11、 rituximab-free medium at 37C for 0-48 h, CDC is analyzed.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Cohorts of tumor-bearing mice (140-180 mm3) are randomized into study groups of 6 to 10 based on the number ofAdministration 1 available mic
12、e. The IDBS electronic notebook statistical package, Biobook, is used for automated animalrandomization. Animals are dosed by intraperitoneal injection (or intravenously for 144580) twice a week for 4 cycleswith ADC, or once a week for 2 cycles with 1.5 mg/kg doxorubicin for breast PDX tumors or 5 m
13、g/kg Cisplatin forovarian PDX. Study groups are followed until either individual mice or entire cohort measurements reach 1,200 mm3,at which point sacrifice is indicated. Tumor regression is defined as a reduction in mean tumor volume after dosing.In cases where tumors regress, time to progression (
14、TTP) is determined to be the number of days between the firstdose and the time at which mean tumor volume significantly increase (regrow) after regression.MCE has not independently confirmed the accuracy of these methods. They are for reference only.户使本产品发表的科研献 PLoS Biol. 2020 Mar 23;18(3):e3000666.
15、Page 2 of 3 www.MedChemE FASEB J. 2018 Jun 6:fj201800092R.See more customer validations on HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Damelin M, et al. Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result inSustained Tumor Re
16、gressions. Clin Cancer Res. 2015 Sep 15;21(18):4165-732. de Vries JF, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acutelymphoblastic leukemia cells. Leukemia. 2012 Feb;26(2):255-643. Takeshita A, et al. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules ofmalignant B-cells. Leukemi
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 材料损坏赔偿协议书模板
- 风管加工及安装合同范本
- 灵活用工合同免责协议书
- 物业股份出售协议书模板
- 福州串串香加盟合同范本
- 经销商代理销售合同范本
- 维护企业权益的合同范本
- 清包保温合同协议书范本
- 深圳出租写字楼合同范本
- 煤炭包销合同协议书模板
- 多囊卵巢综合征诊治路径专家共识
- 医用气体系统维保服务方案
- JJF 2093-2024高加速寿命和应力筛选试验系统校准规范
- 糖尿病急性并发症识别处理和预防护理课件
- 精神科风险评估
- 电机故障诊断培训课件
- 中药临床应用指导原则与合理用药课件
- 《细菌毒素》课件
- 一阶电路习题答案2
- 实习律师指南
- 2023湖北省黄冈市黄梅县黄梅镇招聘社区工作人员12人高频笔试、历年难易点考题(共500题含答案解析)模拟试卷
评论
0/150
提交评论